TNFA -308G>A and IL10 -1082A>G polymorphisms seem to be predictive biomarkers of chronic HCV infection

BMC Infectious Diseases - Tập 21 - Trang 1-8 - 2021
Angélica Menezes Santiago1,2, Ednelza da Silva Graça Amoras1, Maria Alice Freitas Queiroz1, Simone Regina Souza da Silva Conde3,4, Izaura Maria Vieira Cayres-Vallinoto1, Ricardo Ishak1, Antonio Carlos Rosário Vallinoto1
1Laboratory of Virology, Institute of Biological Sciences, Federal University of Pará (Universidade Federal Do Pará - UFPA), Belém, Brazil
2Graduate Program in Virology, Evandro Chagas Institute/SVS/MS, Ananindeua, Brazil
3João de Barros Barreto Hospital, Federal University of Pará (Universidade Federal do Pará - UFPA), Belém, Brazil
4School of Medicine, Institute of Health Sciences, Federal University of Pará (Universidade Federal Do Pará - UFPA), Belém, Brazil

Tóm tắt

Genetic changes may induce dysregulated cytokine production and affect the progression of the chronic disease caused by the hepacivirus C (HCV) because the balance of pro- and anti-inflammatory cytokines determines the outcome of infection. This study evaluated the TNFA -308G>A and IL10 -1082A>G polymorphisms in the susceptibility and progress of chronic hepatitis C. The study included 101 samples from patients with chronic hepatitis C and 300 samples from healthy donors. Polymorphisms were typed by real-time PCR and were analyzed for associations with histopathological parameters (according to METAVIR classification) and HCV viral load. The polymorphic genotype for the TNFA -308G>A variant was not present in the group of patients with chronic hepatitis C and its absence could be associated with protection against HCV infection (p = 0.0477). Patients with the polymorphic genotype of the IL10 -1082A>G polymorphism had higher HCV viral load than wild-type patients (p = 0.0428). Neither polymorphism was associated with different levels of necroinflammatory activity or fibrosis scores. Our results suggest the polymorphic genotype at TNFA -308G>A as protective against chronic HCV infection, and the polymorphic genotype at the IL10 -1082A>G variant associated with higher HCV viral load. Further studies must be performed in order to confirm these associations.

Tài liệu tham khảo

World Health Organization. Hepatitis C. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C virus infection: host–virus interaction and mechanisms of viral persistence. Cells. 2019;8:376. https://doi.org/10.3390/cells8040376. Fallahi P, Ferri C, Ferrari SM, Corrado A, Sansonno D, Antonelli A. Cytokines and HCV-related disorders. Clin Dev Immunol. 2012;2012:468107. https://doi.org/10.1155/2012/468107. Kusumoto K, Uto H, Hayashi K, Takahama Y, Nakao H, Suruki R, et al. Interleukin-10 or tumor necrosis factor-alpha polymorphisms and the natural course of hepatitis C virus infection in a hyperendemic area of Japan. Cytokine. 2006;34:24–31. https://doi.org/10.1016/j.cyto.2006.03.011. Abraham LJ, Kroeger KM. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol. 1999;66:562–6. https://doi.org/10.1002/jlb.66.4.562. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34:391–9. https://doi.org/10.1016/s0161-5890(97)00052-7. Cabrera M, Shaw MA, Sharples C, Williams H, Castes M, Convit J, Blackwell JM. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med. 1995;182:1259–64. https://doi.org/10.1084/jem.182.5.1259. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol. 2008;180:5771–7. https://doi.org/10.4049/jimmunol.180.9.5771. Eskandari-Nasab E, Moghadampour M. The relationship between IFN-γ and TNF-α gene polymorphisms and brucellosis: a meta-analysis. Adv Clin Exp Med. 2018;27:1701–9. https://doi.org/10.17219/acem/75869. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA. 1998;95(16):9465–70. https://doi.org/10.1073/pnas.95.16.9465. Pabalan N, Chaisri S, Tabunhan S, Tarasuk M, Jarjanazi H, Steiner T. Associations of tumor necrosis factor-α-308 polymorphism with dengue infection: a systematic review and meta-analysis. Acta Trop. 2017;173:17–22. https://doi.org/10.1016/j.actatropica.2017.05.007. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1–8. https://doi.org/10.1111/j.1365-2370.1997.tb00001.x. Lesiak A, Zakrzewski M, Przybyłowska K, Rogowski-Tylman M, Wozniacka A, Narbutt J. Atopic dermatitis patients carrying G allele in -1082 G/A IL-10 polymorphism are predisposed to higher serum concentration of IL-10. Arch Med Sci. 2014;10:1239–43. https://doi.org/10.5114/aoms.2014.47833. Meenakshi P, Ramya S, Shruthi T, Lavanya J, Mohammed HH, Mohammed SA, et al. Association of IL-1β +3954 C/T and IL-10-1082 G/A cytokine gene polymorphisms with susceptibility to tuberculosis. Scand J Immunol. 2013;78:92–7. https://doi.org/10.1111/sji.12055. Talaat RM, Esmail AA, Elwakil R, Gurgis AA, Nasr MI. Tumor necrosis factor-alpha -308G/A polymorphism and risk of hepatocellular carcinoma in hepatitis C virus-infected patients. Chin J Cancer. 2012;31:29–35. https://doi.org/10.5732/cjc.011.10258. Gao QJ, Liu DW, Zhang SY, Jia M, Wang LM, Wu LH, Wang SY, Tong LX. Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. World J Gastroenterol. 2009;15(44):5610–9. https://doi.org/10.3748/wjg.15.5610. Moreira ST, Silva GF, de Moraes CF, Grotto RM, de Moura Campos Pardini MI, et al. Influence of cytokine and cytokine receptor gene polymorphisms on the degree of liver damage in patients with chronic hepatitis C. Meta Gene. 2016;9:90–6. https://doi.org/10.1016/j.mgene.2016.04.003. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de DST, Aids e Hepatites Virais. Protocolo clínico e diretrizes terapêuticas para hepatite viral C e coinfecções, 2011. 144 p. Técnicos). https://bvsms.saude.gov.br/bvs/publicacoes/protocolos_diretrizes_hepatite_viral_c_coinfeccoes.pdf. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–93. https://doi.org/10.1002/hep.510240201. Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016;16:509–23. https://doi.org/10.1038/nri.2016.69. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001;19:65–91. https://doi.org/10.1146/annurev.immunol.19.1.65. Holbrook J, Lara-Reyna S, Jarosz-Griffiths H, McDermott M. Tumour necrosis factor signalling in health and disease. F1000Res. 2019. https://doi.org/10.12688/f1000research.17023.1. Boks MA, Kager-Groenland JR, Mousset CM, van Ham SM, ten Brinke A. Inhibition of TNF receptor signaling by anti-TNFα biologicals primes naïve CD4(+) T cells towards IL-10(+) T cells with a regulatory phenotype and function. Clin Immunol. 2014;151:136–45. https://doi.org/10.1016/j.clim.2014.02.008. Bouzgarrou N, Hassen E, Gabbouj S, Schvoerer E, Ben Mami N, Triki H, et al. Lack of effect of tumor necrosis factor-alpha -308 G/A polymorphism on severity of liver fibrosis in Tunisian hepatitis C virus (HCV)-infected patients. Gastroenterol Clin Biol. 2010;34:297–304. https://doi.org/10.1016/j.gcb.2010.03.008. Dogra G, Chakravarti A, Kar P, Chawla YK. Polymorphism of tumor necrosis factor-α and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon-α therapy response. Hum Immunol. 2011;72:935–9. https://doi.org/10.1016/j.humimm.2011.06.008. Santos NP, Ribeiro-Rodrigues EM, Ribeiro-Dos-Santos AK, Pereira R, Gusmão L, Amorim A, Guerreiro JF, Zago MA, Matte C, Hutz MH, Santos SE. Assessing individual interethnic admixture and population substructure using a 48-insertion-deletion (INSEL) ancestry-informative marker (AIM) panel. Hum Mutat. 2010;31:184–90. https://doi.org/10.1002/humu.21159. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29:71–109. https://doi.org/10.1146/annurev-immunol-031210-101312. Bouzgarrou N, Hassen E, Farhat K, Bahri O, Gabbouj S, Maamouri N, et al. Combined analysis of interferon-gamma and interleukin-10 gene polymorphisms and chronic hepatitis C severity. Hum Immunol. 2009;70:230–6. https://doi.org/10.1016/j.humimm.2009.01.019. Ramos JA, Silva R, Hoffmann L, Ramos AL, Cabello PH, Urményi TP, et al. Association of IL-10, IL-4, and IL-28B gene polymorphisms with spontaneous clearance of hepatitis C virus in a population from Rio de Janeiro. BMC Res Notes. 2012;5:508. https://doi.org/10.1186/1756-0500-5-508. Abbas Z, Moatter T, Hussainy A, Jafri W. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3. World J Gastroenterol. 2005;11:6656–61. https://doi.org/10.3748/wjg.v11.i42.6656. Pinto P, Salgado C, Santos NP, Santos S, Ribeiro-dos-Santos A. Influence of genetic ancestry on INDEL markers of NFKb1, CASP8, PAR1, IL4 and CYP19A1 genes in leprosy patients. PLoS Negl Trop Dis. 2015;9:e0004050. https://doi.org/10.1371/journal.pntd.0004050. Pontoriero AC, Trinks J, Hulaniuk ML, Caputo M, Fortuny L, Pratx LB, et al. Influence of ethnicity on the distribution of genetic polymorphisms associated with risk of chronic liver disease in South American populations. BMC Genet. 2015;16:1–8. https://doi.org/10.1186/s12863-015-0255-3. Sheneef A, Esmat MM, Mohammad AN, Mahmoud AA, Moghazy HM, Noureldin AK. Interleukin-10 and interferon gamma gene polymorphisms and hepatitis C virus-related liver cirrhosis risk. J Interferon Cytokine Res. 2017;37:175–80. https://doi.org/10.1089/jir.2016.0106.